[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100633210","screening-and-management-of-adults-with-asthma-and-allergic-diseases-100633210",false,"NCT07523724","Screening and Management of Adults With Asthma and Allergic Diseases","Inclusion Criteria:\n\n* Aged ≥18 years\n* Capable of providing informed consent and completing the questionnaire independently.\n\nExclusion Criteria:\n\n* Individuals with serious chronic diseases, immune disorders, or severe psychiatric\u002Fcognitive conditions.","ALL","18 Years","60 Years",{"count":19,"type":20},9666,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to develop and validate a digital screening tool and digital management system for asthma and allergic diseases among Chinese adults and to evaluate the effectiveness of integrated non-pharmacological interventions in improving disease control and quality of life.\n\nThe digital management cohort consists of:\n\n* At least 12 months of longitudinal monitoring of symptoms, environmental exposures, and health behaviors via a digital platform, supplemented by regular clinical assessments.\n* 3x embedded randomized controlled trials (RCTs) evaluating the clinical efficacy of non-pharmacological strategies: allergen avoidance (anti-mite bedding), physical activity (wearable-guided exercise), and dietary management (Mediterranean diet).",[26,27],"Asthma","Allergic Disease",[29,26,30,31,32],"Allergic diseases","Questionnaire development and validation","Digital health","China","NOT_YET_RECRUITING","2026-04-06",{"date":36,"type":37},"2026-04-13","ACTUAL",{"date":39,"type":20},"2026-09-01",{"date":41,"type":20},"2027-12-30",{"name":43,"class":44},"Beijing Hospital","OTHER_GOV",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100620368","phase-1-a-study-to-find-a-suitable-dose-of-exl-111-for-further-research-100620368","NCT07356713","A Study to Find a Suitable Dose of Exl-111 for Further Research","A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial of Exl-111 in Healthy Participants","Inclusion Criteria:\n\n1. Healthy, male and female participants 18-55 years of age at Screening\n2. Body weight ≥45 kg and ≤120 kg and body mass index (BMI) 18 to ≤32 kg\u002Fm2 at Screening and Day -1\n3. Serum IgE ≥30 IU\u002FmL and ≤300 IU\u002FmL at Screening\n4. Nonsmoker and must not have used any tobacco products within 2 months prior to Screening. Participants who smoke ≤2 cigarettes or equivalent (e.g., cigars, vaping, nicotine patches) per week can be included in the trial at the discretion of the PI\u002Fdelegate\n5. Positive skin prick test at Screening (Part B MAD Cohorts only) to common aeroallergens\n6. Willing and able to read, understand, and sign an informed consent form (ICF) that includes compliance with requirements and restrictions listed in the ICF and in this protocol\n\nExclusion Criteria:\n\n1. Received Exl-111 in a prior cohort in this trial\n2. Prior receipt of any anti-IgE therapy\n3. Use of any medication, including any prescription, over-the-counter, or other supplements, within 5 days prior to dosing, extending to 30 days after last dose of trial intervention, with the exception of those approved by the PI and Sponsor or Sponsor representative.\n4. Receipt of any small molecule investigational agent or trial intervention in a clinical trial within 30 days or 5 half-lives (whichever is longer) prior to Day 1\n5. Receipt of any protein or antibody-based therapeutic agents (e.g., growth hormones or mAbs) within 3 months or 5 half-lives (whichever is longer) prior to Screening\n6. Receipt of either of the following:\n\n   1. Any live\u002Funattenuated vaccinations within 12 weeks prior to Screening\n   2. Non-living\u002Fattenuated vaccinations (including inactivated vaccines, messenger RNA vaccines) within 4 weeks prior to Screening\n7. History of active systemic infection within 30 days prior to Day 1\n8. Known history of positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), human immunodeficiency virus (HIV)-1 or HIV-2\n9. Positive test at Screening for HBsAg, hepatitis B core antibody (HBcAb), HCV Ab, HIV antibody, QuantiFERON®-TB Gold In-Tube test\n10. Active treatment for any allergic condition, except for over-the-counter (OTC) antihistamines for seasonal allergy subject to exclusion #11\n11. In Part B only, use of any drug that may interfere with the skin prick test results, including antihistamine use within 5 days before each skin prick test\n12. History of relevant drug hypersensitivity, or any confirmed significant allergic reactions (urticaria or anaphylaxis), as judged by the PI, against any drug, or multiple drug or food allergies.\n13. History of cardiac arrhythmia or family history of sudden cardiac death or a history of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, hypomagnesia, or family history of Long QT Syndrome)\n14. Clinically relevant history of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, ophthalmological, or connective tissue diseases or disorders that, in the opinion of the PI, might pose additional risk to the participant or confound the results of the trial\n15. History of malignancy in the previous 5 years\n16. History of alcohol or substance use disorder within the previous 5 years\n17. History of vasovagal reactions\n18. History of hereditary alpha-tryptasemia\n19. Positive test result for alcohol or drugs of abuse at Screening or Day -1\n20. Clinical laboratory safety test results outside the local reference range at Screening or Day -1 which are deemed to be clinically significant by PI\u002Fdelegate\n21. AST\u002FALT \\>1.5 × ULN or total bilirubin \\> ULN at Screening or Day -1 (excluding participants with documented history of Gilbert's syndrome)\n22. Screening or Day -1 estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73m2, according to the Chronic Kidney Disease Epidemiology Collaboration equation. Borderline results (±10 mL\u002Fmin\u002F1.73m2) may be acceptable based on PI's discretion.\n23. Screening or Day -1 supine blood pressure (BP) ≥160 mmHg (systolic) or ≥95 mmHg (diastolic), following at least 5 minutes of supine rest. If BP is ≥160 mmHg (systolic) or ≥95 mmHg (diastolic), the BP should be repeated 2 more times (at least 5 minutes between measures) and the average of the 3 BP values should be used to determine the participant's eligibility\n24. Screening supine 12-lead ECG demonstrates a QTcF interval \\>450 msec for male participants or \\>470 msec for female participants, or a QRSD interval \\>120 msec or any other relevant ECG finding at Screening. If the QTcF exceeds 450 msec, or QRSD exceeds 120 msec, the ECG should be repeated 2 more times (at least 5 minutes between measures) and the average of the 3 QTcF or QRSD values should be used to determine the participant's eligibility\n25. Pregnant, lactating, or breastfeeding, or plan to become pregnant while participating in the trial or within 30 days of the last dose of trial intervention\n26. Unwilling or unable to comply with the contraception requirements and lifestyle restrictions\n27. Employee of the Sponsor or the site or a relative of an employee at the site",true,"55 Years",{"count":55,"type":20},70,[57],"PHASE1","This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose trial of Exl-111 in healthy participants.\n\nThe trials consists of 2 parts, as follows:\n\nPart A (SAD): Up to 5 dose cohorts, each with 8 participants, randomized into 2 arms: Exl-111 and placebo.\n\nPart B (MAD): Up to 3 dose cohorts, each with 10 participants, randomized into 3 arms: Exl-111, placebo, and an active comparator (omalizumab).",[27],"RECRUITING","2026-02-17",{"date":63,"type":37},"2026-02-19",{"date":65,"type":37},"2026-01-08",{"date":67,"type":20},"2026-12-07",{"name":69,"class":70},"Excellergy Inc.","INDUSTRY",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":52,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":93,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":71},"100617272","birth-cohort-development-of-ige-autoantibodies-in-newborns-with-high-risk-of-atopic-dermatitis-100617272","NCT07316465","Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis","Development of IgE Autoantibodies in Newborns With Atopic Dermatitis (DIANA) Birth Cohort","DIANA","Inclusion Criteria:\n\nNewborns who are planned to be born at the maternity ward of UZ Brussel with the following criteria:\n\n* 400 newborns with high-risk for AD-development (at least 1 parent or sibling with physician diagnosed atopic dermatitis AND\u002FOR asthma AND\u002FOR allergic rhinitis)\n* 100 newborns with low-risk for AD-development (no parents or siblings with history of atopic dermatitis AND\u002FOR asthma AND\u002FOR allergic rhinitis)\n\nExclusion Criteria:\n\n* Newborns not born at the maternity ward of UZ Brussel\n* Parents with a poor understanding of Dutch, French or English\n* Newborns who are admitted post-partum to the neonatal intensive care unit (gestational age \\\u003C34 weeks) or with medical complications\n* Newborns with severe genetic abnormalities\u002Fbirth defects\n* Newborns whose parents will not be able to attend the study visits for a period of 2 years (location, working hours)","1 Hour","24 Months",{"count":83,"type":20},500,[23],"Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as \"self-reactive antibodies\" or \"autoantibodies\". It is not yet known when and how these self-reactive antibodies develop, so this is what we aim to investigate.\n\nThis study aims to examine the presence of self-reactive antibodies at birth. In other words, the investigators want to study the earliest stage of developing antibodies that target the body's own skin cells. Additionally, factors that contribute to the development of these self-reactive antibodies will be explored as well as the correlation with the development of atopic eczema.\n\nThe study will involve newborns who are at an increased risk of developing atopic eczema due to a family history of asthma, hay fever, or atopic eczema. There will also be a control group of newborns without these characteristics. The study's approach is to examine a portion of the umbilical cord blood, which is routinely collected after birth, to investigate self-reactive antibodies. The goal is to determine whether these self-reactive antibodies are linked to the development of atopic eczema in the first two years of life. For this purpose, follow-ups will be conducted at the ages of 6, 12, and 24 months.\n\nThis study will contribute to an increased understanding of the prevalence of self-reactive antibodies and the factors influencing their development. Moreover, the study will determine whether these antibodies play a role in the prevention of and\u002For serve as predictive factors for the development of atopic eczema.",[87,88,89,90,27,91,92],"Atopic Dermatitis (AD)","Autoantibody","Auto-Immunity","Microbiome, Human","IgE-Mediated Hypersensitivity","Newborn Infant",[94,95,96,97,78],"Birth cohort","Autoantibodies","IgE","Atopic dermatitis","2025-12-18",{"date":100,"type":37},"2026-01-05",{"date":102,"type":37},"2023-10-01",{"date":104,"type":20},"2030-12-31",{"name":106,"class":107},"Universitair Ziekenhuis Brussel","OTHER"]